ProPhase Labs Announces Closing of Public Offering of Common Stock
12. November 2024 16:05 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the...
ProPhase Labs Announces Proposed Public Offering of Common Stock
07. November 2024 16:05 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell...
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
07. August 2024 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call...
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
14. Februar 2024 08:00 ET
|
ProPhase Labs, Inc.
Commercialization of Equivir anticipated after second trial is completed in Q2, 2024 Garden City, NY, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation...